| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb53921c8362f5b3ff79175cbac8bdeb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate |
2019-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6e59acb5f8a815709c83b4611b416ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05d6743db9ebbbd1a68246c629154648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28db2f0ed62c1cbac4d1f503ca28243a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01281eba04c1b51356462637843b3491
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51f7ecda41e9f7d4550937a1d8954302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d661c5a5be394bdc223d9ef1984c7d99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c47380fdcb262d293c9f7f3c9fc50115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd9dee29a1e9aeeed110a7705a89f6be |
| publicationDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021228729-A1 |
| titleOfInvention |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer |
| abstract |
The present invention relates to a special type of non-internalizing binding moiety-drug-conjugates that specifically target LGALS3BP. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to LGALS3BP, said antibody being conjugated to cytotoxic drugs. The invention also comprises methods of the treatment of LGALS3BP-expressing cancer, including administering to a patient the disclosed drug conjugates and pharmaceutical preparations. |
| priorityDate |
2018-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |